Full-Time
Director Global Medical Affairs
Updated on 9/6/2026
BeOne
1,001-5,000 employees
Global oncology therapeutics discovery, development, manufacturing
Compensation Overview
$192.1k - $252.1k/yr
Remote in USA
Remote
Up to 20% travel required.
Master's, PharmD, PhD, MD
 Biology & Biotech |
|---|
Get referred to BeOne
See people who can refer or advise you
- An advanced degree of Master of Science, Doctor of Philosophy, Doctor of Pharmacy, or Doctor of Medicine is required.
- At least 10 years of experience in the pharmaceutical, biotech, or life sciences industry, including at least 6 years in Medical Affairs, digital strategy, omnichannel engagement, customer experience, or related capability-building roles.
- Strong understanding of Medical Affairs, scientific communications, non-promotional engagement, and compliant content development.
- Demonstrated experience supporting Medical Affairs engagement across solid tumor and hematologic oncology therapeutic areas.
- Demonstrated experience translating strategy and customer insights into engagement plans, journeys, playbooks, or scalable operating models.
- Ability to simplify complexity and create clear frameworks that teams can understand, adopt, and scale.
- Strong customer experience mindset with the ability to connect content, channels, data, field interactions, timing, and measurement into coordinated plans.
- Experience working across global, regional, and local stakeholders in a matrixed environment.
- Working knowledge of modular content, content operations, digital engagement, analytics, and customer data concepts.
- Ability to test new approaches while maintaining focus on quality, feasibility, compliance, and measurable value.
- Excellent communication and executive presence, with the ability to influence without authority and bring clarity to ambiguous problems.
- High ownership, initiative, adaptability, and comfort building new capabilities in a fast-moving environment.
- Strong proficiency in Microsoft 365 and omnichannel engagement platforms, CRM, next-best-action tools, analytics dashboards, CMS/DAM systems, Medical/Legal/Regulatory review platforms, HCP insights platforms, Veeva/Vault Medical, third-party media platforms, generative artificial intelligence, and artificial-intelligence-enabled engagement and content capabilities.
- Ability to learn new platforms quickly.
- Ability to travel up to 20%.
- Advance customer experience planning by defining how Medical Affairs engagement can be designed around customer needs, moments that matter, scientific priorities, and measurable outcomes.
- Partner with global and regional Medical Affairs teams to translate strategy, customer insights, and key scientific messages into practical engagement plans across relevant channels and touchpoints.
- Design holistic customer journeys connecting digital, field-enabled, congress, third-party, web, email, social, and other engagement channels.
- Apply segmentation, behavioral insights, customer preferences, and performance data to improve relevance, sequencing, personalization, and coordination of scientific engagement.
- Partner with Scientific Communications, Publications, Medical Information, Field Medical, and content partners to align scientific content with customer journeys, key messages, channel needs, and engagement objectives.
- Advance scalable content approaches that improve reuse, modularity, discoverability, fit-for-channel adaptation, and speed while preserving scientific rigor and non-promotional standards.
- Define content requirements for omnichannel engagement plans, including content needs, channel fit, adaptation requirements, measurement approach, and opportunities to maximize reuse and impact.
- Collaborate with internal and external partners to streamline content activation, Medical/Legal/Regulatory review considerations, channel readiness, and the use of artificial intelligence to scale content and improve efficiency.
- Identify, pilot, and scale capabilities that improve customer experience, engagement effectiveness, and operational efficiency, including artificial-intelligence-supported workflows, analytics, personalization, content discoverability, and emerging engagement models.
- Define success measures and closed-loop learning approaches connecting customer insights, engagement data, content performance, field feedback, and business priorities to optimization decisions.
- Translate data and learnings into recommendations that improve customer journeys, engagement planning, capability roadmaps, and resource prioritization.
- Advance innovation with a focus on operational excellence, compliance, governance, and the evolving needs of global and local Medical Affairs teams.
- Build scalable frameworks, playbooks, templates, and standards that help Medical Affairs teams plan and orchestrate customer-centered engagement consistently across franchises and markets.
- Codify emerging best practices from the Omnichannel Center of Excellence into practical guidance that teams can adopt, adapt, and scale locally.
- Lead education, workshops, and change-management efforts that build omnichannel acumen and strengthen proactive customer experience planning across Medical Affairs teams.
- Establish ways of working, governance expectations, and partnership models that enable efficient planning while maintaining compliance, quality, and scientific integrity.
- Lead through influence, mentor peers and partners, and serve as a functional leader for omnichannel customer experience planning and capability-building.
BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Dongcheng District, China
Founded
2010
Get referred to BeOne
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
- August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
- Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.
What critics are saying
- BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
- Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
- AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.
What makes BeOne unique
- BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
- BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
- Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
Wellness Program
Paid Vacation
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↓ -9%2 year growth
↓ -3%BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.
Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.
BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.
John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.
Seegene USA has received Emergency Use Authorization from the FDA for its Allplex HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR test that simultaneously detects herpes simplex virus types 1 and 2, varicella-zoster virus, and monkeypox virus. It is the first multiplex PCR test designed to support differential diagnosis of viral causes of ulcerative skin lesions in the US market. These pathogens often present with similar clinical symptoms that are difficult to distinguish visually. Research presented at the 2024 Clinical Virology Symposium found that a multiplex PCR assay identified HSV, VZV, or MPXV in 54 out of 966 samples that had previously tested negative using single-pathogen methods. The assay was developed using Seegene's proprietary multiplex PCR technologies and automated product development platform.